



Ionis to present at upcoming investor conferences

November 7, 2024

CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:



- Guggenheim's Inaugural Healthcare Conference on Wednesday, November 13, 2024
- UBS Global Healthcare Conference on Wednesday, November 13, 2024
- Stifel 2024 Healthcare Conference on Monday, November 18, 2024
- Jefferies London Healthcare Conference on Wednesday, November 20, 2024
- Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024
- Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024

A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at <https://ir.ionis.com/events-and-presentations/upcoming-events>. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.

About Ionis Pharmaceuticals

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.

To learn more about Ionis, visit ionis.com and follow us on [X \(Twitter\)](#) and [LinkedIn](#).

Ionis Pharmaceuticals Investor Contact:

D. Wade Walke, Ph.D. – ir@ionis.com – 760-603-2331

Ionis Pharmaceuticals Media Contact:

Hayley Soffer – media@ionis.com – 760-603-4679

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/ionis-to-present-at-upcoming-investor-conferences-302297951.html>

SOURCE Ionis Pharmaceuticals, Inc.